ClinicalTrials.gov Identifier: NCT03197870
Aerpio: Phase 2 Double-Masked, Placebo-controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15 MG Once Daily or 15 MG Twice Daily for 12 Months in Patients with Moderate to Severe Non-Proliferative Diabetic Retinopathy.
Condition: Non-Proliferative Diabetic Retinopathy
Study Type: Interventional
Duration: 12 months
For additional information, please click hereBack to Clinical Research